Eylea boosts Regeneron revenues

Regeneron Pharmaceuticals, Inc., reported an increase in total revenues of 42 percent to $626 million for the quarter ended March 31, which was fueled by growth of Eylea (aflibercept) global net sales of 54 percent to $577 million compared to the first quarter of 2013.

Net sales of Eylea (aflibercept) in the United States increased 14 percent to $359 million from the first quarter of 2013.

Bayer HealthCare LLC commercializes Eylea outside the United States, and in the first quarter of 2014, net sales of Eylea outside of the United States were $218 million, compared to $62 million in the first quarter 2013. Regeneron recognized $61 million from its share of net profit from Eylea sales outside the United States in the first quarter of 2014 after repayment of $14 million in development expenses.